- The Berlin-based health tech start-up Nia Health receives 3.5 million euros in a seed financing round.
- The company originates from the Charité Universitätsmedizin Berlin and operates leading dermatology apps, including “Nia”, the most widely downloaded app for people with atopic dermatitis.
- The company has a network of renowned cooperation partners consisting of pharmaceutical companies, health insurance companies and clinics.
- The great potential lies above all in Nia Health’s expertise in the area of real world evidence. This is completely anonymized medical information from the everyday care of patients. With its help, healthcare can be significantly improved.
The fresh capital will be used for expansion: It is planned to expand the market share in German-speaking countries, launch in other EU countries in the next 24 months and prepare for the US market entry.
Furthermore, the funding will be used to further develop the innovative, AI-based technology that integrates machine vision, natural language processing and teledermatology. The company’s technology is currently being used in a total of five clinical studies, including one at the Charité Universitätsmedizin Berlin to investigate the therapy-accompanying effectiveness of the Nia App – with success: “The Nia Health solution used in the randomised, controlled study shows positive effects on the patients’ quality of life,” emphasises Prof. Dr. med. Margitta Worm, allergist and immunologist at the Charité.
“The seed funding allows us to massively expand our AI and development capabilities to best address the individual needs of patients with chronic skin conditions,” says Oliver Welter, co-founder and CTO of Nia Health. “In addition, we benefit from the cross-sector expertise of our strong consortium of investors. With Ventura BioMed Investors, we have a partner with many years of experience in the pharmaceutical industry on board, while in parallel we can draw on adesso’s expertise to scale our IT landscape.”
Nia Health’s expertise in the area of real world evidence is particularly promising for the future. In contrast to clinical trials, the data shows how therapies are actually used. Pharmaceutical companies and other providers of therapeutic services can use this data to significantly improve care. The growing importance of real world evidence is reflected in Nia Health’s figures: last year alone, the start-up more than doubled its revenue compared to 2021. Its partners include Sanofi, Pfizer, LEO Pharma as well as large statutory health insurers such as the Kaufmännische Krankenkasse KKH or AOK PLUS.
“We have been following the development of Nia Health since its establishment and have been convinced by the venture’s capital-efficient growth in recent years. In the market for real world evidence, we see massive potential – especially in dermatology, where Nia Health addresses an acute gap in care,” says Niels Sharman, Investment Manager at High-Tech Gründerfonds.
Andreas Jenne, CEO of Ventura BioMed Investors, adds: “The founders of Nia Health excited me from the beginning. They understood how to cooperate with insurance companies and the industry at an early stage and thus generate significant revenues.”
About Nia Health
Nia Health is a spin-off of the Charité Universitätsmedizin Berlin. The start-up develops a clinical diagnosis and therapy system for the continuous digital support of patients with chronic skin conditions. With its platform, Nia Health addresses an often highly underserved patient population and generates treatment-relevant real world evidence. With its innovative machine vision approach, Nia Health enables accurate documentation of disease and therapy progression and thus optimised treatment. The company works closely with German patient associations and leading clinicians and has already won reputable customers from the insurance and pharmaceutical industries. Amongst others, the Berlin-based company has developed the award-winning apps in the fields of atopic dermatitis (Nia) and psoriasis (Sorea), which were the first digital medical products of their kind to be approved worldwide. The digital medical solutions from Nia Health provide daily support for thousands of patients and their families.
Media Contact
Victoria Ott, PIABO PR
Nina Pressentin, PIABO PR
nia-medtech@piabo.net
About High-Tech Gründerfonds
The seed investor High-Tech Gründerfonds (HTGF) finances technology start-ups with growth potential and has supported more than 700 start-ups since 2005. With the launch of the fourth fund, HTGF has around 1.4 billion euros under management. The team of experienced investment managers and start-up experts supports the young companies with know-how, entrepreneurial spirit and passion. The focus is on high tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. More than 4.5 billion euros of capital have been invested in the HTGF portfolio by external investors in more than 2,000 follow-on financing rounds to date. In addition, the fund has already successfully sold shares in 170 companies. The fund investors of the public-private partnership include the Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.
Media Contact
High-Tech Gründerfonds Management GmbH
Tobias Jacob, Senior Marketing & Communications Manager
T.: +49 228 – 82300 – 121
t.jacob@htgf.de
